$ cat ./records/gates-foundation-backs-merck-rvsv-zebov-ervebo-first-licensed-ebo-2019.txt
Gates Foundation Backs Merck rVSV-ZEBOV Ervebo — First Licensed Ebola Vaccine
[RECORD.TXT] · cat --full
The Gates Foundation supported the development and deployment pathway for Merck's rVSV-ZEBOV vaccine, which became the world's first licensed Ebola vaccine when it received WHO prequalification in November 2019. The vaccine showed 84 percent effectiveness during the 2018–2020 DRC outbreak. With Gates Foundation and UNICEF partnership support, Merck established the world's first global Ebola vaccine stockpile in January 2021, ensuring doses would be pre-positioned for the next outbreak rather than manufactured reactively — a supply model explicitly advocated for by Bill Gates in his pandemic preparedness writings.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation and Johns Hopkins Host Event 201 Global Pandemic Simulation
Next →
Invested $55 Million in BioNTech Before COVID-19
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.